PART I . Overview We are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Applying our proprietary, differentiated and innovative technologies, and through collaborations with our strategic partners, we have developed multiple approved products for the treatment of Duchenne muscular ...
expected 2026-12-23
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-02 | 2025-12-31 | 0001193125-26-084144 | EDGAR | 118K words |
| 2025-02-28 | 2024-12-31 | 0000950170-25-029973 | EDGAR | 103K words |
| 2024-02-28 | 2023-12-31 | 0000950170-24-022036 | EDGAR | 104K words |
| 2023-02-28 | 2022-12-31 | 0000950170-23-005062 | EDGAR | 101K words |
| 2022-03-01 | 2021-12-31 | 0000950170-22-002517 | EDGAR | 98K words |
| 2021-03-01 | 2020-12-31 | 0001564590-21-009835 | EDGAR | 103K words |
| 2020-02-26 | 2019-12-31 | 0001564590-20-006769 | EDGAR | 96K words |
| 2019-02-28 | 2018-12-31 | 0001564590-19-005170 | EDGAR | 98K words |
| 2018-03-01 | 2017-12-31 | 0001564590-18-004107 | EDGAR | 87K words |
| 2017-02-28 | 2016-12-31 | 0001564590-17-002842 | EDGAR | 79K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-05 | 2026-06-30 | 0001193125-26-335003 | EDGAR | 70K words |
| 2025-11-06 | 2025-09-30 | 0001193125-25-269436 | EDGAR | 74K words |
| 2025-08-06 | 2025-06-30 | 0000950170-25-103971 | EDGAR | 66K words |
| 2025-05-06 | 2025-03-31 | 0000950170-25-064412 | EDGAR | 56K words |
| 2024-11-06 | 2024-09-30 | 0000950170-24-122239 | EDGAR | 62K words |
| 2024-08-07 | 2024-06-30 | 0000950170-24-092720 | EDGAR | 59K words |
| 2024-05-01 | 2024-03-31 | 0000950170-24-051234 | EDGAR | 54K words |
| 2023-11-01 | 2023-09-30 | 0000950170-23-057414 | EDGAR | 62K words |
| 2023-08-02 | 2023-06-30 | 0000950170-23-037125 | EDGAR | 60K words |
| 2023-05-02 | 2023-03-31 | 0000950170-23-016654 | EDGAR | 54K words |
| 2022-11-02 | 2022-09-30 | 0000950170-22-021213 | EDGAR | 63K words |
| 2022-08-02 | 2022-06-30 | 0000950170-22-013863 | EDGAR | 58K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-23 | 0001193125-26-399416 | EDGAR | 1K words |
| 2026-08-05 | 0001193125-26-335056 | EDGAR | 10K words |
| 2026-07-27 | 0001193125-26-316995 | EDGAR | 1K words |
| 2026-02-25 | 0001193125-26-072064 | EDGAR | 0K words |
| 2026-02-25 | 0001193125-26-071566 | EDGAR | 12K words |
| 2026-01-12 | 0001193125-26-010116 | EDGAR | 2K words |
| 2025-12-19 | 0001193125-25-326969 | EDGAR | 3K words |
| 2025-12-11 | 0001193125-25-315032 | EDGAR | 1K words |
| 2025-12-08 | 0001193125-25-310588 | EDGAR | 8K words |
| 2025-11-03 | 0001193125-25-262591 | EDGAR | 11K words |
318 total filings indexed. 286 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000873303 |
| Ticker | SRPT |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.sarepta.com |
| Listed | 1997-06-04 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/SRPT (~200 tokens, structured JSON with cryptographic provenance)